A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population

August 30, 2012 updated by: Afexa Life Sciences Inc

Parents with children aged 3-11 will participate in this study. About 500 children will take part in the study. We expect about half of those children will develop symptoms of a respiratory infection. Active participation in this study will last 14 days after a parent reports symptoms of a respiratory infection in a participant. Those children who do meet the study criteria of symptoms will then be randomly placed (like a flip of a coin) into one of 2 groups to take either COLD-FX® or placebo for 3 days. A placebo will look exactly like COLD-FX® but contains no active ingredients. The participant has an equal chance of being placed in either of the above groups. The study is double-blind, so neither the participant nor the study staff will know which study group the participant was placed in until the study is completed. If this information is needed in an emergency at any time throughout the study, it is quickly available from the sponsor.

Participation in the study will be for 14 days after symptoms of a respiratory infection are reported to study staff. Your child will take the study product for 3 days, you will complete a daily diary, receive 4 phone calls and be seen for a final study visit to review the diary and complete a final health check of your child.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The primary objective is to assess the efficacy of acute dosing of CVT-E002 in reducing the duration of URTI symptoms in children 3-11 years of age.

The secondary objectives are to asses the efficacy of acute dosing of CVT-E002 in reducing: (1) symptom severity; (2) peak CARIFS scores and; (3) absenteeism for participant and/or parent/guardian. The ease of administration and the safety of acute dosing of CVT-E002 in children 3-11 years of age will also be assessed.

Study Type

Interventional

Enrollment (Actual)

293

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T5N 4A3
        • Alberta Health Services
    • New Brunswick
      • Saint John, New Brunswick, Canada, E2L4L2
        • Saint John Regional Hospital
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3K 6R8
        • Canadian Center for Vaccinology, Dalhousie University
    • Ontario
      • Toronto, Ontario, Canada, M4P 1P2
        • JDM Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 11 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Healthy individuals of both genders aged years 3 - 11
  2. Willing to adhere to the requirements of the protocol, including availability for follow-up visits
  3. Parent/guardian willing and able to sign written consent

Exclusion Criteria:

  1. Medical conditions:

    • Asthma requiring treatment in the last 3 months with oral steroids - prednisone greater than 10 mg/day
    • Received influenza vaccination for the winter season when the trial is run.
    • Active tuberculosis
    • Cystic fibrosis
    • Significant pulmonary disorders (chronic bronchitis, emphysema or other chronic respiratory illness)
    • Any ongoing allergen immunotherapy during study or for 6 months prior HIV/AIDS
    • Malignancy (under active observation or treatment)
    • Unstable cardiovascular disease (physician visit or hospitalization for unstable cardiovascular disease in the last 6 months)
    • Known renal abnormalities (serum creatinine known to be > upper limit for age group)
    • Acute or active chronic liver disease
    • Diabetes
    • Neurological or psychiatric disease (progressive or currently under treatment)
    • Bleeding disorders
    • Major surgery in the last 6 months or planned surgery over the course of the study
    • Crohn's disease, Juvenile arthritis, Ulcerative Colitis or any other autoimmune disease
    • Other serious medical conditions

  2. Medications:

    • Medications for allergic rhinitis/conjunctivitis, including: antihistamines; oral, parenteral, nasal, and ophthalmic corticosteroids; cromolyn sodium; nedocromil; and intranasal anticholinergics (If the participants agree to stop taking these products prior to study entry and for the duration of the study, they can participate in the study.)
    • Oral or long-acting beta-agonists, theophylline, and leukotriene modifiers
    • Phenelzine
    • Pentobarbital
    • Haloperidol
    • Warfarin
    • Heparin

    • Immunosuppressants

      • Any other natural health products or dietary supplements, with the exception of vitamins and minerals with dose of <600 mg/day of vitamin E and containing no vitamin K. Natural health products or dietary supplements include products such as, but not limited to, Echinacea, Ginseng (beverages, foods, extracts, capsules, or tablets), St. John's Wort, Gingko, Glucosamine, Fish Oil supplements, Evening Primrose Oil, Green Tea or other herbal products consumed in the form of a pill or capsule. (If the participants agree to stop taking these products prior to study entry and for the duration of the study, they can participate in the study.)
  3. Known allergy to any ingredient in the study product or placebo, including: ginseng, icing sugar, stevia leaf powder, mixed berries natural flavour (MC010946), grape natural flavour (MC010947) or caramel color liquid (DN700 caramelan 8-110).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: 2
Other: Placebo
3 day, once daily dosing
Active Comparator: 1
Other: North American ginseng
3 day, once daily, dosing
Other Names:
  • COLD-FX

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The primary objective is to assess the efficacy of acute dosing of CVT-E002 in reducing the duration of URTI symptoms in children 3-11 years of age
Time Frame: 14 days
14 days

Secondary Outcome Measures

Outcome Measure
Time Frame
To asses the efficacy of acute dosing of CVT-E002 in reducing: (1) symptom severity; (2) peak CARIFS scores and; (3) absenteeism for participant and/or parent/guardian.
Time Frame: 14 days
14 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Afexa Life Sciences Inc

Investigators

  • Principal Investigator: Shelly McNeil, FRCPC, Dalhousie University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2009

Primary Completion (Actual)

April 1, 2012

Study Completion (Actual)

April 1, 2012

Study Registration Dates

First Submitted

August 25, 2009

First Submitted That Met QC Criteria

August 25, 2009

First Posted (Estimate)

August 26, 2009

Study Record Updates

Last Update Posted (Estimate)

August 31, 2012

Last Update Submitted That Met QC Criteria

August 30, 2012

Last Verified

August 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CVT-E002-2007-3

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Upper Respiratory Tract Infections

Clinical Trials on North American ginseng

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe